the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine
Yiwu, Zhejiang, 322000, China
Location status: Recruiting
Location contact
lin dong
CONTACT
NCT Number: NCT06492083
The combination of platinum and taxane drugs has a chemotherapy-induced peripheral neuropathy (CIPN) rate of 73% to 83%. Its symptoms can not only limit daily activities and cause a variety of accidental injuries, but also easily cause negative emotions and seriously affect the quality of life. Modern Western medicine lacks effective clinical intervention methods, and the treatment of acupuncture points with traditional Chinese medicine is simple to operate, easy to observe adverse reactions, and is suitable for continuous self-treatment outside the hospital after training, saving patients time to travel to and from the hospital, and high patient acceptance. Due to the similarity of the pathogenesis of some traditional Chinese and Western medicine in CIPN and the effectiveness of its application in patients with DPN, this study evaluated the effect of specific formulations of Chinese medicine on CIPN by comparing the degree of nerve damage between the following formulations of Chinese medicine hot packs in patients with platinum combined with paclitaxel chemotherapy and the control group.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Yiwu, Zhejiang, 322000, China
Location status: Recruiting
lin dong
CONTACT
A random group generator was used to divide the sample of 90 cases, and 45 cases in the control group and 45 cases in the intervention group.
Control group: The chemotherapy was strictly followed by the drug use routine, administered by central vein, paclitaxel and platinum administration rate were set at 180ml/h, and routine health guidance was given before and after chemotherapy.
Intervention group: In addition to the usual nursing measures of the control group, traditional Chinese medicine hot bao acupoint treatment and home care were used.
Patients in both the intervention and control groups were assessed for peripheral neuropathy on the 14th day after the completion of each two rounds of chemotherapy, and the NCI-CTCAE, FACT/GOG-Ntx, and KPSS score scales were assigned according to the patient-reported outcomes.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
traditional Chinese medicine hot bag
Time frame: 6 months
National Cancer Institute-Common Terminology Criteria for Adverse Events. Scoring form 1 to 5 degree.
Time frame: 6 months
National Cancer Institute-Common Terminology Criteria for Adverse Events. Scoring from 1 to 5 degree.
Time frame: 6 months
Functional assessment of cancer therapy /gynaecologic oncology group-neuro-toxicity.Scoring from 0 to 4.
Time frame: 6 months
Functional assessment of cancer therapy /gynaecologic oncology group-neuro-toxicity.Scoring from 0 to 4.
Time frame: 6 months
Functional assessment of cancer therapy /gynaecologic oncology group-neuro-toxicity.Scoring from 0 to 4.
Time frame: 6 months
Functional assessment of cancer therapy /gynaecologic oncology group-neuro-toxicity.Scoring from 0 to 4.
Time frame: 6 months
Functional assessment of cancer therapy /gynaecologic oncology group-neuro-toxicity.Scoring from 0 to 4.
Contact information is provided by the study sponsor or research team.
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Other
A Randomized Controlled Clinical Stuty on the Treatment and Nursing Care of CIPN Patients With Traditional Chinese Medicine Hot Package
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07731477
Breast Cancer, Breast Diseases
Ankara, Turkey (Türkiye)
View Trial DetailsNCT07175376
Cancer, Chemotherapy
Charlotte, North Carolina, United States
View Trial DetailsNCT07339488
Borderline Resectable Carcinoma, Carcinoma
Shantou, Guangdong, China
View Trial DetailsNCT04889924
Axillary Lymph Nodes Dissection, Breast Cancer
Sydney, New South Wales, Australia
View Trial Details